Suven Life Sciences has surged 6% to Rs 81.45 after the company announced that it has secured three products patents each from Australia, Sri Lanka and South Korea corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.
With these new patents, Suven has a total of 16 granted patents from Australia, 9 granted patents from Sri Lanka and 12 granted patents from South Korea, the company said in a press release.
The company has 12 internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia, it added.
The stock opened at Rs 75.80 and touched high of Rs 81.45 on the BSE. A combined 2.61 million shares already changed hands on the counter till 1000 hours against an average sub one million shares that were traded daily in past two weeks.
With these new patents, Suven has a total of 16 granted patents from Australia, 9 granted patents from Sri Lanka and 12 granted patents from South Korea, the company said in a press release.
The company has 12 internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia, it added.
The stock opened at Rs 75.80 and touched high of Rs 81.45 on the BSE. A combined 2.61 million shares already changed hands on the counter till 1000 hours against an average sub one million shares that were traded daily in past two weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%